A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease

医学 酒精性肝病 脂肪肝 内科学 比较器 胃肠病学 疾病 物理 量子力学 电压 肝硬化
作者
Manuel Romero‐Gómez,Eric Lawitz,R. Ravi Shankar,Eirum Chaudhri,Jie Liu,Raymond L. H. Lam,Keith D. Kaufman,Samuel S. Engel,Santiago Oscar Bruzone,Maria Jimena Coronel,Fernando Gruz,Ignacio MacKinnon,Jacob George,Kate Muller,Samuel S. Lee,Cyrielle Caussy,Jean‐Michel Petit,Ziv Ben Ari,Marius Braun,Helena Katchman
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:79 (4): 888-897 被引量:83
标识
DOI:10.1016/j.jhep.2023.05.013
摘要

This study assessed the effects of the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide relative to the selective GLP-1 receptor agonist semaglutide on liver fat content (LFC) in patients with non-alcoholic fatty liver disease (NAFLD).This was a phase IIa, randomized, active-comparator-controlled, parallel-group, open-label study. A magnetic resonance imaging-estimated proton density fat fraction assessment was performed to determine LFC at screening and Week 24. Participants with an LFC of ≥10% at screening were randomized 1:1 to efinopegdutide 10 mg or semaglutide 1 mg, both administered subcutaneously once weekly for 24 weeks. Participants were stratified according to the concurrent diagnosis of type 2 diabetes mellitus (T2DM). Both drugs were titrated to the target dose over an 8-week time period. The primary efficacy endpoint was relative reduction from baseline in LFC (%) after 24 weeks of treatment.Among 145 randomized participants (efinopegdutide n = 72, semaglutide n = 73), 33.1% had T2DM. At baseline, mean BMI was 34.3 kg/m2 and mean LFC was 20.3%. The least squares (LS) mean relative reduction from baseline in LFC at Week 24 was significantly (p <0.001) greater with efinopegdutide (72.7% [90% CI 66.8-78.7]) than with semaglutide (42.3% [90% CI 36.5-48.1]). Both treatment groups had an LS mean percent reduction from baseline in body weight at Week 24 (efinopegdutide 8.5% vs. semaglutide 7.1%; p = 0.085). Slightly higher incidences of adverse events and drug-related adverse events were observed in the efinopegdutide group compared with the semaglutide group, primarily related to an imbalance in gastrointestinal adverse events.In patients with NAFLD, treatment with efinopegdutide 10 mg weekly led to a significantly greater reduction in LFC than semaglutide 1 mg weekly.EudraCT: 2020-005136-30; NCT: 04944992.Currently, there are no approved therapies for non-alcoholic steatohepatitis (NASH). The weight loss associated with glucagon-like peptide-1 (GLP-1) receptor agonists has been shown to decrease hepatic inflammation in patients with NASH. In addition to reducing liver fat content (LFC) indirectly through weight loss, glucagon receptor agonism may also reduce LFC by acting on the liver directly to stimulate fatty acid oxidation and reduce lipogenesis. This study demonstrated that treatment of patients with non-alcoholic fatty liver disease with the GLP-1/glucagon receptor co-agonist efinopegdutide (10 mg weekly) led to a significantly greater reduction in LFC compared to treatment with the GLP-1 receptor agonist semaglutide (1 mg weekly), suggesting that efinopegdutide may be an effective treatment for NASH.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CipherSage应助yyymmma采纳,获得10
刚刚
2秒前
Kin完成签到,获得积分10
2秒前
3秒前
3秒前
今后应助紫紫吃菠菜采纳,获得10
4秒前
呆萌笑晴发布了新的文献求助10
4秒前
5秒前
5秒前
5秒前
zyf1980发布了新的文献求助10
6秒前
小二郎应助22222采纳,获得10
8秒前
rff666发布了新的文献求助10
8秒前
jouholly发布了新的文献求助10
9秒前
甘草发布了新的文献求助10
12秒前
yyymmma完成签到,获得积分10
12秒前
12秒前
jellorio发布了新的文献求助10
12秒前
14秒前
CodeCraft应助科研通管家采纳,获得10
15秒前
8R60d8应助科研通管家采纳,获得10
15秒前
8R60d8应助科研通管家采纳,获得10
15秒前
隐形曼青应助科研通管家采纳,获得10
15秒前
脑洞疼应助科研通管家采纳,获得10
15秒前
8R60d8应助科研通管家采纳,获得10
16秒前
科研通AI2S应助科研通管家采纳,获得10
16秒前
飞翔的蒲公英完成签到,获得积分10
16秒前
ding应助科研通管家采纳,获得10
16秒前
8R60d8应助科研通管家采纳,获得10
16秒前
小二郎应助科研通管家采纳,获得10
16秒前
8R60d8应助科研通管家采纳,获得10
16秒前
猪猪hero应助科研通管家采纳,获得10
16秒前
叮咚完成签到,获得积分10
16秒前
18秒前
彭于晏应助稳重的画板采纳,获得10
18秒前
21秒前
在水一方应助orange采纳,获得10
21秒前
22秒前
22秒前
安详的雅旋完成签到,获得积分10
23秒前
高分求助中
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3962917
求助须知:如何正确求助?哪些是违规求助? 3508861
关于积分的说明 11143755
捐赠科研通 3241789
什么是DOI,文献DOI怎么找? 1791689
邀请新用户注册赠送积分活动 873065
科研通“疑难数据库(出版商)”最低求助积分说明 803579